Open-arm, Japan Expanded Access Program With Lanadelumab (TAK-743) for Japanese Patients With Hereditary Angioedema
Latest Information Update: 13 Oct 2024
At a glance
- Drugs Lanadelumab (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Expanded access; Registrational
- Sponsors Takeda
- 01 Jun 2023 The protocol of this study has been amended as Primary endpoints has been amended and trial focus has now shifted to Ar only.
- 01 Jul 2022 Status changed from active, no longer recruiting to completed.
- 02 Jun 2022 Planned End Date changed from 31 Jul 2022 to 31 Aug 2022.